Science News – Scientific Sessions 2022

Welcome to #AHA22 Science News!

This is where you will find in-depth interviews from investigators and AHA experts on the Tier 1 late-breaking clinical trials during Scientific Sessions 2022. Expect at-a-glance summaries, analysis, and more!

Here are some important links:

Monday was the final day of Scientific Sessions presentation, but it was by no means the least exciting. #AHA22 Program co-chair Amit Khera and Manesh Patel give us a recap.


Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
Robert J Mentz | Duke University Hospital, Durham, North Carolina


Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension
Areef Ishani | Minneapolis VA Health Care System, Minneapolis, Minnesota


A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
Aruna D Pradhan, Brigham and Women's Hospital | Boston, Massachusetts


First-in-Human in vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Julian D Gillmore | University College of London, London, United Kingdom

2022 Scientific Sessions Presidential Session

Don't miss the Presidential Session -- with AHA CEO Nancy Brown and AHA President Michelle A. Albert, as well as this year's distinguished scientists and Chairman's Award winners.


Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The STRESS Trial
Kevin D Hill | Duke Pediatric and Adult Congenital Heart Center, Durham, North Carolina


Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial
Petr Ostadal, Na Homolce Hosp, Prague, Czech Republic


The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial
Eric B. Loucks | Brown University, Providence, Rhode Island


Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial
David Preiss | University of Oxford, Oxford, United Kingdom


Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial
Pamela S Douglas | Duke University School of Medicine, Durham, North Carolina


Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results
Alik Farber | Boston Medical Center, Boston, Massachusetts

Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses
Matthew T Menard | Brigham and Women's Hospital, Boston, MA


Successful Post-Discharge of Heart Failure
Alexandre Mebazaa | University de Paris, Paris, France


Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the RAPID Study
James E Ip | Weill Cornell School of Medicine, New York, NY


Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial
David E Kandzari | Piedmont Heart Institute, Atlanta, GA